These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept. Tyagi P; Juma Z; Hor YK; Scott NW; Ionean A; Santiago C BMC Ophthalmol; 2018 Jun; 18(1):148. PubMed ID: 29929478 [TBL] [Abstract][Full Text] [Related]
3. Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study. Clemens CR; Wolf A; Alten F; Milojcic C; Heiduschka P; Eter N Acta Ophthalmol; 2017 Nov; 95(7):683-689. PubMed ID: 28084038 [TBL] [Abstract][Full Text] [Related]
4. Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography. Clemens CR; Alten F; Termühlen J; Mihailovic N; Rosenberger F; Heiduschka P; Eter N Graefes Arch Clin Exp Ophthalmol; 2020 Jul; 258(7):1411-1417. PubMed ID: 32306096 [TBL] [Abstract][Full Text] [Related]
6. Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration. Rouvas A; Chatziralli I; Androu A; Mpougatsou P; Alonistiotis D; Douvali M; Kabanarou SA; Theodossiadis P Int Ophthalmol; 2019 Feb; 39(2):431-440. PubMed ID: 29404860 [TBL] [Abstract][Full Text] [Related]
7. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study. Sarraf D; London NJ; Khurana RN; Dugel PU; Gune S; Hill L; Tuomi L Ophthalmology; 2016 Oct; 123(10):2213-24. PubMed ID: 27566855 [TBL] [Abstract][Full Text] [Related]
8. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration. Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442 [TBL] [Abstract][Full Text] [Related]
9. QUANTITATIVE ANALYSIS OF PIGMENT EPITHELIAL DETACHMENT RESPONSE TO DIFFERENT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN WET AGE-RELATED MACULAR DEGENERATION. Balaskas K; Karampelas M; Horani M; Hotu O; Keane P; Aslam T Retina; 2017 Jul; 37(7):1297-1304. PubMed ID: 27755376 [TBL] [Abstract][Full Text] [Related]
10. GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response. de Massougnes S; Dirani A; Mantel I Retina; 2018 Apr; 38(4):717-724. PubMed ID: 28368974 [TBL] [Abstract][Full Text] [Related]
13. Response of Pigment Epithelial Detachment to Anti-Vascular Endothelial Growth Factor Treatment in Age-Related Macular Degeneration. Cho HJ; Kim KM; Kim HS; Lee DW; Kim CG; Kim JW Am J Ophthalmol; 2016 Jun; 166():112-119. PubMed ID: 27048998 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Intravitreal Injection of Ranibizumab for Neovascular Age-Related Macular Degeneration with Serous Pigment Epithelial Detachment. Zhao C; Zhang Z; Chen L; Wang F; Xu D Med Sci Monit; 2016 Mar; 22():833-9. PubMed ID: 26972376 [TBL] [Abstract][Full Text] [Related]
15. Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration. Dirani A; Ambresin A; Marchionno L; Decugis D; Mantel I Am J Ophthalmol; 2015 Oct; 160(4):732-8.e2. PubMed ID: 26144701 [TBL] [Abstract][Full Text] [Related]
16. One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD: a prospective study. Veritti D; Sarao V; Parravano M; Arias L; Varano M; Lanzetta P Eur J Ophthalmol; 2017 Jan; 27(1):74-79. PubMed ID: 27791249 [TBL] [Abstract][Full Text] [Related]
17. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration. Park DH; Sun HJ; Lee SJ Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933 [TBL] [Abstract][Full Text] [Related]
18. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255 [TBL] [Abstract][Full Text] [Related]
19. OUTCOME OF INTRAVITREAL AFLIBERCEPT FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OR WITHOUT SUBRETINAL FLUID AND SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Kim K; Kim ES; Kim Y; Yang JH; Yu SY; Kwak HW Retina; 2019 Feb; 39(2):303-313. PubMed ID: 29160779 [TBL] [Abstract][Full Text] [Related]
20. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects. de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]